Australia - English - Department of Health (Therapeutic Goods Administration)

i-medix pty ltd - 59822 - skin photodynamic therapy/phototherapy lamp - led lamp for dermatologic purpose, clinically intended for treatment of inflammatory skin conditions such as acne and pigmentary disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 12282 - light, surgical - intended for use in hospital treatment rooms and operating theatres to provide localised lighting for examination of a patient, or during a surgical procedure. these lights can be ceiling-mounted, wall-mounted or mobile.

European Union - English - EMA (European Medicines Agency)

pinnacle biologics b.v.  - porfimer sodium - barrett esophagus - antineoplastic agents - photodynamic therapy (pdt) with photobarr is indicated for: ablation of high-grade dysplasia (hgd) in patients with barrett's oesophagus (bo)

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

biofrontera pharma gmbh - aminolevulinic acid hydrochloride - gel - 78mg/1gram

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - aminolevulinic acid hydrochloride 10.2mg equivalent to aminolevulinic acid 8mg - dermal patch - 8 mg - active: aminolevulinic acid hydrochloride 10.2mg equivalent to aminolevulinic acid 8mg excipient: durotak 387-2353 scotchpak 1109 (baking film) pegoterate - treatment of mild to moderate actinic ketatoses (ak) lesions on the face and scalp.

Ireland - English - HPRA (Health Products Regulatory Authority)

spirig pharma europe gmbh - 5-aminolevulinic acid hydrochloride - medicated plaster - 8 milligram

European Union - English - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv)

European Union - English - EMA (European Medicines Agency)

life molecular imaging gmbh - florbetaben (18f) - radionuclide imaging; alzheimer disease - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.neuraceq is a radiopharmaceutical indicated for positron emission tomography (pet) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for alzheimer’s disease (ad) and other causes of cognitive impairment. neuraceq should be used in conjunction with a clinical evaluation.a negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of ad.

Australia - English - Department of Health (Therapeutic Goods Administration)

allied biotech australia pty ltd -

Malta - English - Medicines Authority

curium austria gmbh grazer strasse 18 a-8071 hausmanstaetten , austria - solution for injection - fludeoxyglucose 1 gbq/ml - diagnostic radiopharmaceuticals